Impact of proximal promoter polymorphisms on AHR gene expression in human lung

描述（由申请人提供）：自发现以来，芳烃受体（AhR）已被认为是由烟雾中的多环芳烃和其他不完全燃烧产生的致癌物引发的致癌过程的组成部分。AhR调节一组编码I相细胞色素P450单加氧酶、II相结合酶和III相代谢物转运蛋白的基因的表达，这些基因代谢和处理PAH致癌物，同时也引起有限水平的反应性致突变中间体。尽管AhR在人肺的致癌过程中至关重要，但控制AhR表达的潜在分子机制尚未完全建立。最近，我们确定了四个新的变体的重复多态性，包括两个以前未报道的单核苷酸多态性重复内，人类AHR基因，并建立了一种新的方法来分析它们。这些新的多态性发生在近端启动子的关键控制区，该启动子包含特异性蛋白质转录因子的多个结合位点。我们的中心假设是，这些新的特点AHR基因多态性影响AhR表达的转录调控，这反过来又导致改变表达和诱导的致癌物生物活化酶，以及第二阶段和第三阶段的失活途径。本申请的具体目的是：1）确定肺癌患者正常组织中AHR基因的这些新多态性的等位基因频率，和2）确定这些新多态性在AhR表达的转录调节中的作用。我们将在体外进行肺肿瘤细胞系中转录因子结合和AHR启动子活性的测定，并确定这些多态性杂合个体的正常肺组织中AhR mRNA的等位基因表达。这些研究将确定AHR基因启动子中新的多态性对AhR表达的重要性，并可能最终导致对肺癌遗传易感性的更清晰的理解。

DESCRIPTION (provided by applicant): Since its discovery, the aryl hydrocarbon receptor (AhR) has been recognized as an integral component of the carcinogenic process initiated by smoke-born polycyclic aromatic hydrocarbons and other carcinogens that result from incomplete combustion. The AhR regulates the expression of a group of genes encoding phase I cytochrome P450 monooxygenases, phase II conjugating enzymes, and phase III metabolite transporters that metabolize and dispose of PAH carcinogens, while also causing a limited level of reactive, mutagenic intermediates. Despite the pivotal importance of the AhR in the carcinogenic process in human lung, the underlying molecular mechanisms controlling AhR expression are not well established. Recently, we identified four novel variants of a repeat polymorphism, including two previously unreported single-nucleotide polymorphisms within the repeat, of the human AHR gene and have established a new method for analyzing them. These novel polymorphisms occur in a critical control region of the proximal promoter that contains multiple binding sites for specificity protein transcription factors. Our central hypothesis is tha these newly characterized AHR gene polymorphisms affect the transcriptional regulation of AhR expression, which in turn leads to altered expression and inducibility of the carcinogen-bioactivating enzymes as well as phase II and III pathways of deactivation. The specific aims of our application are: 1) to determine the allelic frequencies of these novel polymorphisms of the AHR gene in normal tissue from lung cancer patients, and 2) to determine the roles of these novel polymorphisms in the transcriptional regulation of AhR expression. We will perform in vitro assays of transcription factor binding and AHR promoter activities in a lung tumor cell line and determine allelic expression of AhR mRNA in normal lung tissue from individuals heterozygous for these polymorphisms. These studies will determine the importance of novel polymorphisms in the AHR gene promoter on AhR expression and may ultimately lead to a clearer understanding of the genetic susceptibility to lung cancer.